HomeCompareAZLOF vs ABBV

AZLOF vs ABBV: Dividend Comparison 2026

AZLOF yields 6666.67% · ABBV yields 3.09%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AZLOF wins by $1028095347812061.75M in total portfolio value
10 years
AZLOF
AZLOF
● Live price
6666.67%
Share price
$0.03
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1028095347812062.00M
Annual income
$998,628,545,336,266,700,000.00
Full AZLOF calculator →
ABBV
AbbVie Inc.
● Live price
3.09%
Share price
$214.96
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$103.7K
Annual income
$25,324.79
Full ABBV calculator →

Portfolio growth — AZLOF vs ABBV

📍 AZLOF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAZLOFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AZLOF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AZLOF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AZLOF
Annual income on $10K today (after 15% tax)
$566,666.67/yr
After 10yr DRIP, annual income (after tax)
$848,834,263,535,826,600,000.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$262.96/yr
After 10yr DRIP, annual income (after tax)
$21,526.07/yr
At 15% tax rate, AZLOF beats the other by $848,834,263,535,826,600,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AZLOF + ABBV for your $10,000?

AZLOF: 50%ABBV: 50%
100% ABBV50/50100% AZLOF
Portfolio after 10yr
$514047673906031.06M
Annual income
$499,314,272,668,133,360,000.00/yr
Blended yield
97.13%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

AZLOF
No analyst data
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+19.2% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AZLOF buys
0
ABBV buys
7
PoliticianChamberTickerTypeAmountDate
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-18
Julia Letlow🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-08
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-11-13
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-31
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-30
Lisa McClain🏢 House$ABBV▲ Buy$1,001 - $15,0002025-10-30
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-08-14
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-11
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAZLOFABBV
Forward yield6666.67%3.09%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$1028095347812062.00M$103.7K
Annual income after 10y$998,628,545,336,266,700,000.00$25,324.79
Total dividends collected$1026118102492338.88M$62.2K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: AZLOF vs ABBV ($10,000, DRIP)

YearAZLOF PortfolioAZLOF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$677,367$666,666.67$11,555$434.96+$665.8KAZLOF
2$42,928,313$42,203,530.63$13,485$635.47+$42.91MAZLOF
3$2,545,616,701$2,499,683,405.64$15,933$937.67+$2545.60MAZLOF
4$141,255,910,403$138,532,100,533.89$19,118$1,400.80+$141255.89MAZLOF
5$7,335,374,338,812$7,184,230,514,680.15$23,384$2,125.24+$7335374.32MAZLOF
6$356,516,885,536,661$348,668,034,994,132.70$29,290$3,286.81+$356516885.51MAZLOF
7$16,218,956,689,966,618$15,837,483,622,442,392.00$37,776$5,205.38+$16218956689.93MAZLOF
8$690,711,023,145,868,900$673,356,739,487,604,600.00$50,495$8,488.44+$690711023145.82MAZLOF
9$27,539,067,734,387,980,000$26,800,006,939,621,900,000.00$70,497$14,346.44+$27539067734387.91MAZLOF
10$1,028,095,347,812,062,000,000$998,628,545,336,266,700,000.00$103,718$25,324.79+$1028095347812061.75MAZLOF

AZLOF vs ABBV: Complete Analysis 2026

AZLOFStock

Azelio AB (publ) manufactures and supplies Stirling engine-based renewable energy solutions in Sweden. It offers Thermal Energy Storage – Power on Demand (TES.POD), a thermal energy storage system. The company was incorporated in 2006 and is headquartered in Gothenburg, Sweden.

Full AZLOF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this AZLOF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AZLOF vs SCHDAZLOF vs JEPIAZLOF vs OAZLOF vs KOAZLOF vs MAINAZLOF vs JNJAZLOF vs MRKAZLOF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.